First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.

ABSTRACT:

Introduction

As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients.

Methods

This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100 mg/100 mg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated.

Results

The data showed that danoprevir boosted by ritonavir is safe and well t

SUBMITTER: Chen H 

PROVIDER: S-EPMC7710192 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature